We are on site at the Fira Gran Via in Barcelona, Spain, at the 2019 ESMO Congress!
We’ll be recapping some of the top news presented each day during the meeting, and soon we’ll speak with both Drs Suresh Ramalingam and David Spigel on some breakthrough studies in lung cancer.
Welcome to OncLive News Network! I’m Gina Columbus.
In non—small cell lung cancer, frontline treatment with osimertinib improved median overall survival by 6.8 months compared with erlotinib or gefitinib for patients with metastatic, EGFR-mutant disease despite crossover between arms, according to eagerly awaited updated findings from the phase III FLAURA study.
The median OS in the osimertinib arm was 38.6 months compared with 31.8 months with erlotinib or gefitinib, representing a 20% reduction in the risk of death with the third-generation EGFR inhibitor. At the final data cutoff for the study, 54% of patients remained alive at 36 months in the osimertinib arm compared with 44% in the erlotinib/gefitinib group.
Also in lung cancer, a final analysis of part 1 of the phase III CheckMate-227 trial showed that the first-line combination of nivolumab and ipilimumab led to a clinically meaningful improvement in overall survival compared with chemotherapy in patients with advanced non—small cell lung cancer, regardless of PD-L1 expression status.
In a cohort of patients with PD-L1 expression ≥1%, the median OS with nivolumab and ipilimumab compared with chemotherapy was 17.1 months and 14.9 months, respectively. Moreover, the median OS was 17.1 months with the combination and 13.9 months with chemotherapy in patients regardless of PD-L1 expression status.
That’s all for today. Stay tuned for tomorrow’s OncLive News Network: On Location, where we will sit down with Drs Suresh Ramalingam and David Spigel on lung cancer studies.
Thank you for watching OncLive News Network! I’m Gina Columbus.